Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

Sean Yates, Ravi Sarode

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

Original languageEnglish (US)
JournalCurrent Neurology and Neuroscience Reports
Issue number1
StatePublished - 2015
Externally publishedYes


  • Anticoagulants
  • Apixaban
  • Dabigatran
  • Intracerebral hemorrhage
  • Prothrombin complex concentrate
  • Rivaroxaban
  • Target-specific oral anticoagulants
  • Vitamin K
  • Warfarin

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage'. Together they form a unique fingerprint.

Cite this